User profiles for R. Walsky

Robert Walsky

EMD Serono Inc
Verified email at emdserono.com
Cited by 3805

[PDF][PDF] In vitro cytochrome P450 inhibition data and the prediction of drug‐drug interactions: qualitative relationships, quantitative predictions, and the rank‐order …

RS Obach, RL Walsky, K Venkatakrishnan… - Clinical Pharmacology …, 2005 - academia.edu
Drug-drug interactions (DDIs) represent a serious problem in clinical practice. However,
with knowledge gained over the past 15 years on the human drugmetabolizing enzymes, a …

Evaluation of a new molecular entity as a victim of metabolic drug-drug interactions—an industry perspective

…, YH Wang, M Sinz, R Stearns, R Walsky… - Drug Metabolism and …, 2016 - ASPET
Under the guidance of the International Consortium for Innovation and Quality in Pharmaceutical
Development (IQ), scientists from 20 pharmaceutical companies formed a Victim Drug-…

Validated assays for human cytochrome P450 activities

RL Walsky, RS Obach - Drug metabolism and disposition, 2004 - ASPET
The measurement of the effect of new chemical entities on human cytochrome P450 marker
activities using in vitro experimentation represents an important experimental approach in …

The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions

RS Obach, RL Walsky, K Venkatakrishnan… - … of Pharmacology and …, 2006 - ASPET
The accuracy of in vitro inhibition parameters in scaling to in vivo drug-drug interactions (DDI)
was examined for over 40 drugs using seven human P450-selective marker activities in …

Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions

RS Obach, RL Walsky, K Venkatakrishnan - Drug metabolism and …, 2007 - ASPET
The ability to use vitro inactivation kinetic parameters in scaling to in vivo drug-drug interactions
(DDIs) for mechanism-based inactivators of human cytochrome P450 (P450) enzymes …

Examination of 209 drugs for inhibition of cytochrome P450 2C8

RL Walsky, EA Gaman… - The Journal of Clinical …, 2005 - Wiley Online Library
Cytochrome P450 2C8 is involved in the metabolism of drugs such as paclitaxel, repaglinide,
rosiglitazone, and cerivastatin, among others. An in vitro assessment of 209 frequently …

Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors

RL Walsky, JN Bauman, K Bourcier, G Giddens… - Drug Metabolism and …, 2012 - ASPET
The measurement of the effect of new chemical entities on human UDP-glucuronosyltransferase
(UGT) marker activities using in vitro experimentation represents an important …

Selective inhibition of human cytochrome P4502C8 by montelukast

RL Walsky, RS Obach, EA Gaman, JPR Gleeson… - Drug metabolism and …, 2005 - ASPET
The leukotriene receptor antagonist montelukast was examined for its inhibition of the
human drug-metabolizing enzyme cytochrome P4502C8 (CYP2C8). Montelukast was …

Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6

RL Walsky, AV Astuccio… - The Journal of Clinical …, 2006 - Wiley Online Library
Cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of drugs such as bupropion,
efavirenz, propofol, and selegiline, among others. More than 200 commonly prescribed …

Prediction of time-dependent CYP3A4 drug–drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme …

KR Yeo, RL Walsky, M Jamei… - European Journal of …, 2011 - Elsevier
Predicting the magnitude of time-dependent metabolic drug–drug (mDDIs) interactions involving
cytochrome P-450 3A4 (CYP3A4) from in vitro data requires accurate knowledge of the …